Pulse Biosciences, Inc (NASDAQ:PLSE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Pulse Biosciences, Inc (NASDAQ:PLSE) has been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $45.25.

A number of equities analysts have recently issued reports on the company. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Needham & Company LLC initiated coverage on Pulse Biosciences in a report on Monday. They set a “buy” rating and a $58.00 price objective for the company. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research note on Monday, August 10th. Canaccord Genuity Group increased their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Pulse Biosciences during the first quarter valued at $323,000. Creative Planning lifted its stake in shares of Pulse Biosciences by 26.3% during the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after buying an additional 3,951 shares in the last quarter. Legal & General Group Plc boosted its holdings in Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock worth $338,000 after buying an additional 8,197 shares during the period. Norges Bank purchased a new stake in Pulse Biosciences in the 2nd quarter worth $302,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences in the second quarter worth about $158,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Price Performance

NASDAQ:PLSE opened at $44.54 on Monday. The firm has a market capitalization of $3.08 billion, a P/E ratio of -37.75 and a beta of 1.61. Pulse Biosciences has a 12-month low of $12.56 and a 12-month high of $46.97. The stock’s fifty day simple moving average is $30.86 and its 200-day simple moving average is $24.74.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, equities research analysts expect that Pulse Biosciences will post -1.29 earnings per share for the current year.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.